Overview

REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients

Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
A phase 2 study, aiming to evaluate the efficacy, safety and pharmacokinetics of REC 0/0559 in treatment of Neurotrophic Keratitis in Adult Patient in Europe and United States of America.
Phase:
Phase 2
Details
Lead Sponsor:
Recordati Rare Diseases
Collaborator:
Syneos Health
Treatments:
Ophthalmic Solutions